Integrated Ultrasound-Enrichment and Machine Learning in Colorimetric Lateral Flow Assay for Accurate and Sensitive Clinical Alzheimer's Biomarker Diagnosis.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
PMID:

Abstract

The colloidal gold nanoparticle (AuNP)-based colorimetric lateral flow assay (LFA) is one of the most promising analytical tools for point-of-care disease diagnosis. However, the low sensitivity and insufficient accuracy still limit its clinical application. In this work, a machine learning (ML)-optimized colorimetric LFA with ultrasound enrichment is developed to achieve the sensitive and accurate detection of tau proteins for early screening of Alzheimer's disease (AD). The LFA device is integrated with a portable ultrasonic actuator to rapidly enrich microparticles using ultrasound, which is essential for sample pre-enrichment to improve the sensitivity, followed by ML algorithms to classify and predict the enhanced colorimetric signals. The results of the undiluted serum sample testing show that the protocol enables efficient classification and accurate quantification of the AD biomarker tau protein concentration with an average classification accuracy of 98.11% and an average prediction accuracy of 99.99%, achieving a limit of detection (LOD) as sensitive as 10.30 pg mL. Further point-of-care testing (POCT) of human plasma samples demonstrates the potential use of LFA in clinical trials. Such a reliable lateral flow immunosensor with high precision and superb sensing performance is expected to put LFA in perspective as an AD clinical diagnostic platform.

Authors

  • Shuqing Wang
    School of Biomedical Engineering, College of Chemistry and Environmental Engineering, The Institute for Advanced Study (IAS), Shenzhen University, Shenzhen, Guangdong, 518060, P. R. China.
  • Yan Zhu
    Department of Chemistry, Xixi Campus, Zhejiang University, Hangzhou, 310028, China. Electronic address: zhuyan@zju.edu.cn.
  • Zhongzeng Zhou
    College of Chemistry and Environmental Engineering, School of Biomedical Engineering of Health Science Center, Shenzhen University, Shenzhen, Guangdong, China518060.
  • Yong Luo
    Laboratory Department of the First Affiliated Hospital of Shenzhen University, Shenzhen, 518000, China.
  • Yan Huang
    Department of Neurology, University of Texas Health Science Center at Houston, Houston, TX.
  • Yibiao Liu
    Longgang District Central Hospital of Shenzhen, Shenzhen, Guangdong, 518116, P. R. China.
  • Tailin Xu
    School of Biomedical Engineering, Shenzhen University, Shenzhen, Guangdong, 518060, China; Guangdong Laboratory of Artificial Intelligence and Digital Economy (SZ), Shenzhen University, Guangdong, 518060, China. Electronic address: xutailin@ustb.edu.cn.